Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

(TM), a late-stage vaccine candidate for the treatment of advanced prostate cancer, was acquired as part of the partnership that was entered with the National Cancer Institute. Very promising data were reported, showing prolonged survival combined with a favourable safety profile. Phase III studies expected to be initiated in 2010. - MVA-BN(R) Anthrax, a new preclinical programme for an anthrax vaccine, is expected to enter clinical trials in 2010. - MVA-BN(R) HIV multiantigen, in development as prophylactic and therapeutic vaccine against HIV, initiated clinical Phase I/II trials. - The company's MVA-BN(R) based prostate cancer vaccine also entered clinical Phase I/II trials. - A milestone payment of USD 25 million was received after submission of important IMVAMUNE(R) data. - The data that were generated from a larger Phase II study with IMVAMUNE(R) was submitted to the US health authorities for evaluation whether they can potentially support the use of IMVAMUNE(R) in a declared emergency. - More than 2,400 subjects have now been vaccinated with IMVAMUNE(R) - The first IMVAMUNE(R) contracts outside USA were signed with Canada and an Asian country.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "2008 was a successful year for Bavarian Nordic where all our primary goals were achieved. We implemented a new strategy, and this has already borne fruit. Our increased focus on cancer therapies which through to the partnership with the NCI led to the acquisition of PROSTVAC(TM) has strengthened our pipeline and we feel very optimistic about our cancer vaccines in the future. At the end of the year, we submitted the important safety data for IMVAMUNE(R) to the US health authorities and are now awaiting just one approval in order to initiate the delivery of the 20 million doses under the RFP-3
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... for the American Society for Reproductive Medicine (ASRM), a ... in reproductive medicine. In his new role as ... executive board and will have a voice in furthering ... actively supported ASRM since 1984 when he joined while ...
(Date:12/24/2014)... CA (PRWEB) December 23, 2014 Pipette.com ... where their Twitter followers can submit their #HolidayInTheLab pictures ... and their lab mates. , For those struggling to ... mates, the Pipette.com Holiday in the Lab Contest provides ... Pipette.com Twitter followers to send pictures of their ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... Editors Note: The Wisconsin Technology Council has ... industry. The 24-page publication highlights the states research ... key contacts and the I-Q Corridor that joins ... Wisconsin Technology Network has arranged to post excerpts ...
... , a supplier of automotive systems and facility management ... its processes. Jim Hayes, the companys delivery systems manager, ... , a Florida-based company that wrote its Analytic Freedom ... ,The software automatically categorizes words and phrases and looks ...
... / CMMI Evolution, not revolution , ,Your ... annual PMI membership dues. Youve been to training, regularly ... your pillow (osmosis). The methodology on your desk is ... Ill bet you could recite the cost control section ...
Cached Biology Technology:Life Sciences: Wisconsin - The Smart Choice Part Two 2Life Sciences: Wisconsin - The Smart Choice Part Two 3Life Sciences: Wisconsin - The Smart Choice Part Two 4Life Sciences: Wisconsin - The Smart Choice Part Two 5Life Sciences: Wisconsin - The Smart Choice Part Two 6Life Sciences: Wisconsin - The Smart Choice Part Two 7Part 5 Project Performance Get on the path to continuous improvement 2Part 5 Project Performance Get on the path to continuous improvement 3Part 5 Project Performance Get on the path to continuous improvement 4
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... PAUL (August 1, 2011) Using state-of-the-art, 7 Tesla magnetic ... researchers may have uncovered a better approach to diagnosing ... was able to cure eight patients of all epileptic ... seizures or convulsions, impacts about one percent of the ...
... 2011, Shenzhen, China and San Diego, CA BGI, ... Inc., a privately held biotechnology company that utilizes a ... discovery and design of new products and processes for ... study on the genomic sequence of the Chinese hamster ...
... A new source of very cold electrons will improve the ... to a trillionth of a second. The study published ... researchers from the ARC Centre of Excellence for Coherent X-ray ... Professor Robert Scholten from the University,s School of Physics ...
Cached Biology News:U of M researchers use improved imaging technique; discover a better approach to diagnosing epilepsy 2Genome of CHO-K1 provides new insights into optimization of biopharmaceutical protein production 2Genome of CHO-K1 provides new insights into optimization of biopharmaceutical protein production 3Cold electrons to aid better design of drugs and materials 2
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: